Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

Conditions

• Cannabis Dependence

Eligibility Criteria

Sex

ALL

Age

21 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo blood collection
• Cannabis sativa Extract — DRUG
  Vape THC
• Nicotine — DRUG
  Vape active nicotine
• Placebo Administration — DRUG
  Vape placebo nicotine
• Questionnaire Administration — OTHER
  Ancillary studies

Study Details

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Key Dates

Start date

May 15, 2026

Status verified

Mar 2026

Primary completion

Mar 1, 2028

Completion

Mar 1, 2028

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Arm A (placebo, THC, nicotine)
  Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. * VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. * VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. All participants also undergo blood sample collection throughout the trial.
• Experimental: Arm B (placebo, THC, nicotine)
  Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. * VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. * VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. All participants also undergo blood sample collection throughout the trial.
• Experimental: Arm C (placebo, THC, nicotine)
  Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. * VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. * VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. All participants also undergo blood sample collection throughout the trial.

Primary Outcome Measure

Maximum concentration of THC in plasma (Cmax) [ Time Frame: Up to 21 days ]

Locations (1)

Find similar trials in Buffalo, NY

Related Studies

• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
  Recruiting · Yale University · New Haven, Connecticut
• Neuroimaging of Adolescent Cannabis Use Treatment
  Recruiting · Indiana University · Indianapolis, Indiana